50,578 Eli Lilly and Company $LLY Shares Acquired by Retirement Systems of Alabama

Retirement Systems of Alabama boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 25.8% in the third quarter, Holdings Channel reports. The fund owned 246,991 shares of the company’s stock after acquiring an additional 50,578 shares during the period. Eli Lilly and Company accounts for 0.8% of Retirement Systems of Alabama’s investment portfolio, making the stock its 21st biggest holding. Retirement Systems of Alabama’s holdings in Eli Lilly and Company were worth $285,788,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Coastal Bridge Advisors LLC acquired a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $2,959,000. Birinyi Associates Inc. grew its holdings in shares of Eli Lilly and Company by 32.6% during the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock worth $1,689,000 after purchasing an additional 359 shares in the last quarter. Mosaic Family Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 70.6% during the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after purchasing an additional 1,430 shares in the last quarter. Heritage Investors Management Corp grew its holdings in shares of Eli Lilly and Company by 6.5% during the 3rd quarter. Heritage Investors Management Corp now owns 11,774 shares of the company’s stock worth $13,624,000 after purchasing an additional 718 shares in the last quarter. Finally, Capital Investment Advisors LLC increased its position in shares of Eli Lilly and Company by 51.3% during the third quarter. Capital Investment Advisors LLC now owns 44,851 shares of the company’s stock valued at $51,896,000 after purchasing an additional 15,214 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: In a Phase 3 trial, Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity in adults with obesity or overweight. Lilly reported up to an average 44% reduction in breathing interruptions and said it plans to seek U.S. FDA approval for the indication by year-end 2026. An additional use could expand the pill’s commercial opportunity and help it compete with Novo Nordisk’s obesity treatments. Article: Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial
• Positive Sentiment: Jefferies raised its LLY price target to $1,700 from $1,610 and reiterated a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Article: Jefferies raises Eli Lilly price target
• Positive Sentiment: Lilly is expanding digital access to Zepbound and Foundayo through telehealth partnerships with Hims & Hers and LifeMD, potentially broadening the reach of its branded obesity medicines. Article: Eli Lilly opens digital access to obesity drugs
• Negative Sentiment: The FDA issued new warnings about a potential serious eye risk associated with GLP-1 drugs, including Zepbound. The safety alert may raise concerns for patients and prescribers, although the reports provided no Lilly-specific change to the drug’s safety profile. Article: FDA orders new eye-risk warnings for Ozempic and Zepbound

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. HSBC upped their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research note on Thursday, September 10th. Cantor Fitzgerald raised their target price on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an “overweight” rating in a research report on Monday, November 2nd. Weiss Ratings downgraded shares of Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday, October 30th. Citigroup boosted their price target on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a report on Friday, October 30th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,416.64.

Eli Lilly and Company Stock Up 4.4%

NYSE LLY opened at $1,413.22 on Tuesday. The firm has a market cap of $1.33 trillion, a PE ratio of 45.87, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,453.00. The stock’s 50 day simple moving average is $1,220.13 and its 200 day simple moving average is $1,102.83. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the previous year, the company posted $7.02 EPS. The business’s revenue for the quarter was up 38.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.